- Home
- SVRA vs CYRX Comparison
SVRA vs CYRX Comparison
Compare SVRA & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- CYRX
- Stock Information
- Founded
- SVRA 2007
- CYRX 1999
- Country
- SVRA United States
- CYRX United States
- Employees
- SVRA N/A
- CYRX N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- CYRX Health Care
- Exchange
- SVRA Nasdaq
- CYRX Nasdaq
- Market Cap
- SVRA 527.2M
- CYRX 438.7M
- IPO Year
- SVRA N/A
- CYRX N/A
- Fundamental
- Price
- SVRA $3.41
- CYRX $9.80
- Analyst Decision
- SVRA Buy
- CYRX Strong Buy
- Analyst Count
- SVRA 8
- CYRX 10
- Target Price
- SVRA $6.63
- CYRX $12.20
- AVG Volume (30 Days)
- SVRA 1.1M
- CYRX 573.5K
- Earning Date
- SVRA 11-11-2025
- CYRX 11-06-2025
- Dividend Yield
- SVRA N/A
- CYRX N/A
- EPS Growth
- SVRA N/A
- CYRX N/A
- EPS
- SVRA N/A
- CYRX 1.35
- Revenue
- SVRA N/A
- CYRX $237,879,000.00
- Revenue This Year
- SVRA N/A
- CYRX N/A
- Revenue Next Year
- SVRA N/A
- CYRX $9.09
- P/E Ratio
- SVRA N/A
- CYRX $7.26
- Revenue Growth
- SVRA N/A
- CYRX 24.93
- 52 Week Low
- SVRA $1.89
- CYRX $4.58
- 52 Week High
- SVRA $4.30
- CYRX $10.46
- Technical
- Relative Strength Index (RSI)
- SVRA 52.33
- CYRX 56.74
- Support Level
- SVRA $3.42
- CYRX $9.28
- Resistance Level
- SVRA $3.65
- CYRX $9.81
- Average True Range (ATR)
- SVRA 0.12
- CYRX 0.47
- MACD
- SVRA -0.04
- CYRX -0.02
- Stochastic Oscillator
- SVRA 12.90
- CYRX 52.47
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.